JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 29, 2026, 16:22Aysha O’Connor: One of the Hardest Parts of My Own Fertility Journey Was Loneliness…
-
Oct 29, 2026, 16:15Chaithra S K: Preimplantation Genetic Testing Still Requires an Embryo Biopsy
-
Oct 29, 2026, 16:11Filipina Woman’s Journey of Strength, Hope, and Finding Balance While Living with PCOS – PCOS Millennials
-
Oct 29, 2026, 15:58Eric Lameignere: Can DNA Fragmentation in Cumulus Cells Predict ICSI Outcomes?
-
Oct 29, 2026, 15:50Saadat Hassan: Sperm Function Testing – Can Advanced Diagnostics Guide IVF and ICSI Selection?
-
Oct 29, 2026, 15:34Sara Spiro: Celebrating the Stories Members Have Trusted With at Maven Clinic – Here Is Mine
-
Oct 29, 2026, 15:31Dina Ibrahem: 0 Motility, 1 Critical Decision
-
Oct 29, 2026, 15:28AI and Automation in Fertility and Genomics: Pipeline or Pipe Dream? – ARCS
-
Oct 29, 2026, 15:26Michael Schindler: Large Networks or Small Centers – Who Delivers Better Care?